149 related articles for article (PubMed ID: 34070610)
1. Synthesis and Biological Evaluation of Spirocyclic Chromane Derivatives as a Potential Treatment of Prostate Cancer.
Feng L; Yu S; Wang H; Yang S; Li X; Dai H; Zhao L; Jiang C; Wang Y
Molecules; 2021 May; 26(11):. PubMed ID: 34070610
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Xiang Q; Wang C; Wu T; Zhang C; Hu Q; Luo G; Hu J; Zhuang X; Zou L; Shen H; Wu X; Zhang Y; Kong X; Liu J; Xu Y
J Med Chem; 2022 Jan; 65(1):785-810. PubMed ID: 34962793
[TBL] [Abstract][Full Text] [Related]
3. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and inĀ vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel chroman derivatives as non-selective acetyl-CoA carboxylase inhibitors.
Wei Q; Mei L; Chen P; Yuan X; Zhang H; Zhou J
Bioorg Chem; 2020 Aug; 101():103943. PubMed ID: 32554277
[TBL] [Abstract][Full Text] [Related]
7. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
8. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Ferla S; Bassetto M; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3636-40. PubMed ID: 27301368
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORĪ³ Inverse Agonist.
Wu X; Shen H; Zhang Y; Wang C; Li Q; Zhang C; Zhuang X; Li C; Shi Y; Xing Y; Xiang Q; Xu J; Wu D; Liu J; Xu Y
J Med Chem; 2021 Jun; 64(12):8775-8797. PubMed ID: 34121397
[TBL] [Abstract][Full Text] [Related]
10. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Pertusati F; Ferla S; Bassetto M; Brancale A; Khandil S; Westwell AD; McGuigan C
Eur J Med Chem; 2019 Oct; 180():1-14. PubMed ID: 31288149
[TBL] [Abstract][Full Text] [Related]
11. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
13. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
14. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
Watts FM; Pouland T; Bunce RA; Berlin KD; Benbrook DM; Mashayekhi M; Bhandari D; Zhou D
Eur J Med Chem; 2018 Oct; 158():720-732. PubMed ID: 30245396
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities.
Rawat P; Verma SM
Drug Des Devel Ther; 2016; 10():2779-88. PubMed ID: 27621598
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.
Nammalwar B; Bunce RA; Berlin KD; Benbrook DM; Toal C
Eur J Med Chem; 2019 May; 170():16-27. PubMed ID: 30878829
[TBL] [Abstract][Full Text] [Related]
19. Organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation.
Zhou R; Wu Q; Guo M; Huang W; He X; Yang L; Peng F; He G; Han B
Chem Commun (Camb); 2015 Aug; 51(66):13113-6. PubMed ID: 26186061
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
Chen H; Xu F; Liang X; Xu BB; Yang ZL; He XL; Huang BY; Yuan M
Bioorg Med Chem Lett; 2015 Jan; 25(2):285-7. PubMed ID: 25488843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
